Diridavumab represents a highly specialized fully human broadly neutralizing monoclonal antibody specifically engineered to target the highly conserved stem region of the influenza A virus hemagglutinin with exceptional binding affinity and selectivity, effectively facilitating the measurable blockade of the pH-induced conformational change required for membrane fusion across various preclinical experimental models to evaluate the prophylactic efficacy against diverse influenza subtypes during strictly monitored laboratory observation periods.